EVOLUT™ R
FORWARD 30-DAY OUTCOMES
PRESENTED AT THE TCT ANNUAL MEETING
OCTOBER 31, 2016
OBJECTIVE/PRIMARY ENDPOINT

- FORWARD is a multicenter, prospective, single-arm, observational post-market study to evaluate safety and performance of the Evolut™ R system in a routine hospital setting.
  - Objective: To document the clinical and device performance outcomes of the Evolut™ R system used in routine hospital practice
  - Primary Endpoint: The all-cause mortality rate at 30 days
  - Sample Size: 1000 patients
  - Present Analysis: Interim 30-day results in first 300 patients
SECONDARY ENDPOINTS

EFFICACY

- Absence of procedural mortality
- Correct positioning of a single prosthetic heart valve into the proper anatomical location
- Absence of patient-prosthesis mismatch, mean gradient < 20 mmHg (or peak velocity < 3 m/sec), and no moderate or severe prosthetic valve regurgitation
- Hemodynamic performance at 24 hours to 7 days (discharge) and 1 year

SAFETY

- VARC-II Safety Composite Endpoint and Components at 30 days post procedure
  - All-cause mortality, All stroke, Life-threatening bleeding, Acute kidney injury: stage 2 or 3, Coronary artery obstruction requiring intervention, Major vascular complication, and valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)
- Rate of new permanent pacemaker implant at 30 days post procedure

Gastrointestinal hemorrhage precluding anticoagulation
INCLUSION AND EXCLUSION CRITERIA

INCLUSION

- Symptomatic native aortic valve stenosis or surgical bioprosthetic valve failure
- Acceptable candidate for elective treatment with the Evolut™ R System in conformity with the local regulatory context
- Age ≥ 80 years OR considered to be at high or greater risk for surgical aortic valve replacement (AVR) where high risk is defined as:
  - STS predicted risk of mortality ≥ 8%
  - Heart team agreement of risk for AVR due to frailty or comorbidities

EXCLUSION

- Contraindication to aspirin, heparin, bivalirudin, ticlopidine, clopidogrel, Nitinol, contrast media
- Mechanical heart valve in aortic position
- Sepsis, including active endocarditis
- Anatomically not suitable for the Evolut™ R system
- Estimated life expectancy < 1 year
- Participating in another trial that may influence the outcome of this trial
- Need for emergency surgery for any reason
# BASELINE CLINICAL CHARACTERISTICS

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N = 300</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>82.0 ± 5.7</td>
</tr>
<tr>
<td>Female</td>
<td>67.3</td>
</tr>
<tr>
<td>STS Score (%)</td>
<td>5.6 ± 3.8</td>
</tr>
<tr>
<td>&lt; 4%</td>
<td>43.3</td>
</tr>
<tr>
<td>4-8%</td>
<td>40.0</td>
</tr>
<tr>
<td>&gt; 8%</td>
<td>16.7</td>
</tr>
<tr>
<td>EuroSCORE II (%)</td>
<td>5.6 ± 4.8</td>
</tr>
<tr>
<td>NYHA III/IV</td>
<td>72.6</td>
</tr>
<tr>
<td>Diabetes</td>
<td>30.0</td>
</tr>
<tr>
<td>Serum creatinine &gt; 2 mg/dl</td>
<td>7.4</td>
</tr>
<tr>
<td>Chronic lung disease (COPD)</td>
<td>24.5</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>14.7</td>
</tr>
<tr>
<td>Frailty</td>
<td>34.1</td>
</tr>
<tr>
<td>Assisted living</td>
<td>13.2</td>
</tr>
</tbody>
</table>
# PROCEDURAL OUTCOMES

<table>
<thead>
<tr>
<th>Characteristic - %</th>
<th>N = 300</th>
</tr>
</thead>
<tbody>
<tr>
<td>General anesthesia</td>
<td>37.0</td>
</tr>
<tr>
<td>Iliofemoral access route</td>
<td>98.3</td>
</tr>
<tr>
<td>Implanted valve size</td>
<td></td>
</tr>
<tr>
<td>23 mm</td>
<td>7.0</td>
</tr>
<tr>
<td>26 mm</td>
<td>40.5</td>
</tr>
<tr>
<td>29 mm</td>
<td>52.5</td>
</tr>
<tr>
<td>Pre-TAVR balloon dilation performed</td>
<td>49.0</td>
</tr>
<tr>
<td>Post-implant dilatation performed</td>
<td>33.4</td>
</tr>
<tr>
<td>EnVeo InLine™ sheath used</td>
<td>92.6</td>
</tr>
<tr>
<td>Multiple valve (≥ 2 implanted)</td>
<td>1.3</td>
</tr>
</tbody>
</table>
30-DAY ALL-CAUSE MORTALITY

No. at risk 300

Medtronic
PROCEDURAL DATA

- **Correct Positioning of Single Valve in Proper Anatomical Location**: 99.0%
- **Absence of Moderate/Severe Patient Prosthesis Mismatch**: 78.4%
- **Mean Gradient < 20 mmHg or Peak Velocity < 3 m/sec**: 98.1%
- **Absence of Moderate or Severe Prosthetic Regurgitation**: 97.3%

*Implant depth as assessed by aortography and reported by the sites:
NCS: 4.8 ± 2.7 mm
LCS: 6.0 ± 2.8 m*

---

1 Patient Prosthesis Mismatch: Defined as AVA < 0.85 cm²/m² for subjects with BMI < 30 kg/cm², or < 0.7 cm²/m² for subjects with BMI ≥ 30 kg/cm
VARC-II SAFETY ENDPOINTS AT 30 DAYS

VARC-II Combined Safety Endpoint = 10.1%

- All-cause Mortality: 2.0%
- Cardiovascular Mortality: 2.0%
- All Stroke: 3.0%
- Life-Threatening or Disabling Bleeding: 2.7%
- Acute Kidney Injury Stage 2/3: 1.0%
- Coronary Artery Obstruction: 0.0%
- Major Vascular Complication: 2.7%
- Valve-Related Dysfunction\(^1\): 1.7%

\(^1\) Valve-related dysfunction requiring repeat procedure
## ADDITIONAL 30-DAY SAFETY ENDPOINTS

<table>
<thead>
<tr>
<th>Event, Kaplan-Meier Rate (%)</th>
<th>N = 300</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial infarction</td>
<td>0.3</td>
</tr>
<tr>
<td>New pacemaker¹</td>
<td>15.4</td>
</tr>
<tr>
<td>Prosthetic valve thrombosis</td>
<td>0.0</td>
</tr>
<tr>
<td>Prosthetic valve endocarditis</td>
<td>0.0</td>
</tr>
<tr>
<td>Valve embolization*</td>
<td>1.0</td>
</tr>
<tr>
<td>Valve migration</td>
<td>0.0</td>
</tr>
<tr>
<td>Mitral valve apparatus damage</td>
<td>0.0</td>
</tr>
</tbody>
</table>

¹ Subjects with pacemaker or ICD at baseline are included in the denominator.

* Per VARC II; all 3 were pop-outs
Patients who underwent resheath/recapture had a similar mortality rate (1.3% vs. 2.3%) and pacemaker implantation rate (13.3% vs. 16.2%) as those who did not undergo resheath/recapture.

* Deployment of the bioprosthesis can be attempted 3 times.
HEMODYNAMIC VALVE PERFORMANCE*

- Effective Orifice Area
  - Baseline: 0.8 ± 0.3
  - Discharge: 42.5 ± 17.7

- Mean Gradient
  - Baseline: 8.7 ± 6.9
  - Discharge: 1.9 ± 0.6

Mean Gradient: n = 270
EOA: n = 267

* Echocardiographic Core Lab
PARAVALVULAR REGURGITATION*

- None/Trace: 71.6%
- Mild: 25.6%
- Moderate: 2.4%
- Severe: 0.4%

* Echocardiographic Core Lab
NYHA CLASS

NYHA Change from Baseline to 30 Days

- Improved: 78.9%
- No Change: 19.5%
- Worsened: 1.6%

Percent of Patients

- Baseline (N = 241):
  - NYHA I: 26.4%
  - NYHA II: 64.9%
  - NYHA III: 1.0%

- 30 Days (N = 227):
  - NYHA I: 40.9%
  - NYHA II: 48.2%
  - NYHA III: 0.8%
CONCLUSIONS

- Interim results at 30 days in this real-world, global experience with Evolut™ R demonstrate:
  - Low incidence of all-cause mortality, stroke and major vascular complications
  - Reduced pacemaker rate post TAVR
  - Excellent hemodynamic results and low rate of moderate/severe PVR
  - Resheath/recapture was used in 25% of cases
- Primary endpoint for 1000 patients at EuroPCR 2017
60 sites in 23 countries
Enrollment to date: 805
INDICATIONS The Medtronic CoreValve and CoreValve Evolut R systems are indicated for use in patients with symptomatic heart disease due to either severe native calcific aortic stenosis or failure (stenosed, insufficient, or closed) of a surgical bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, Society of Thoracic Surgeons predicted risk of operative mortality score ≥8% or at a ≥15% risk of mortality at 30 days).

CONTRAINDICATIONS The CoreValve and CoreValve Evolut R systems are contraindicated for patients presenting with any of the following conditions: known hypersensitivity or contraindication to aspirin, heparin (HIT/HITTS) and bivalirudin, ticlopidine, clopidogrel, Nitinol (Titanium or Nickel), or sensitivity to contrast media, which cannot be adequately premedicated; ongoing sepsis, including active endocarditis; preexisting mechanical heart valve in aortic position.

WARNINGS General Implantation of the CoreValve and CoreValve Evolut R systems should be performed only by physicians who have received Medtronic CoreValve training. This procedure should only be performed where emergency aortic valve surgery can be performed promptly.

Mechanical failure of the delivery catheter system and/or accessories may result in patient complications. Transcatheter Aortic Valve (Bioprosthesis) Accelerated deterioration of the bioprosthesis may occur in patients presenting with an altered calcium metabolism.

PRECAUTIONS General The safety and effectiveness of the CoreValve and CoreValve Evolut R systems have not been evaluated in the pediatric population. The safety and effectiveness of the bioprosthesis for aortic valve replacement have not been evaluated in the following patient populations: patients who do not meet the criteria for symptomatic severe native aortic stenosis as defined: (1) symptomatic severe high gradient aortic stenosis – aortic valve area ≤1.0cm2 or aortic valve area index ≤0.6 cm2/m2, a mean aortic valve gradient ≥40 mmHg; or a peak aortic-jet velocity ≥4.0 m/s, (2) symptomatic severe low-flow/low-gradient aortic stenosis – aortic valve area ≤1.0 cm2 or aortic valve area index ≤0.6 cm2/m2, a mean aortic valve gradient ≤20 mmHg, or a peak aortic- jet velocity ≤4.0 m/s; who are at moderate or low surgical risk (predicted perioperative mortality risk of <15%); with untreated, clinically significant coronary artery disease requiring revascularization; with a preexisting prosthetic heart valve with a rigid support structure in either the mitral or pulmonic position if either the preexisting prosthetic heart valve could affect the implantation or function of the bioprosthesis or the implantation or function of the preexisting prosthetic heart valve; with cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support. The safety and effectiveness of a CoreValve or CoreValve Evolut R bioprosthesis implanted within a failed preexisting transcatheter bioprosthesis has not been demonstrated. Implanting a CoreValve or CoreValve Evolut R bioprosthesis in a failed transcatheter aortic bioprosthesis: (i) a surgical bioprosthetic aortic valve (TAV in SAV]) should be avoided in the following conditions. The degenerated surgical bioprosthesis presents with a significant concomitant perivalvular leak (between the prosthesis and the native annulus), is not securely fixed in the native annulus, or is not structurally intact (eg, wireframe frame fracture); partially detached leaflet in the aortic position may obstruct a coronary orifice that is labeled as stenotic. The safety and effectiveness of the bioprosthesis for aortic valve replacement have not been evaluated in patient populations presenting with the following: blood dyscrasias as defined: leukopenia (WBC <1000 cells/mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states; congenital bicuspid or unicuspid valve; mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation [3–4+]; moderate to severe [3–4+] or severe [4+] mitral or severe [4+] tricuspid regurgitation; hypertrophic obstructive cardiomyopathy; new or untreated echocardiographic evidence of intracardiac mass, thrombus, or vegetation; native aortic annulus size ≤18 mm or >29 mm for CoreValve and ≤18 mm or >30 mm for CoreValve Evolut R per the baseline diagnostic imaging or surgical bioprosthetic aortic annulus size ≤17 mm or >29 mm for CoreValve and ≤17 mm or >30 mm for CoreValve Evolut R; transverse plane aortic root dimension to accommodate an 18 Fr introducer sheath or the 14 Fr equivalent EnVeo R InLine sheath when using Model ENVEOR-US or transarterial access not able to accommodate a 20 Fr introducer sheath or the 16 Fr equivalent EnVeo R InLine sheath when using Model ENVEOR-N-US; sinus of valsalva anatomy that would prevent adequate coronary perfusion; moderate to severe mitral stenosis; severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20%; symptomatic carotid or vertebral artery disease; severe basal septal hypertrophy with an outflow gradient.

Prior to Use Exposure to glutaraldehyde may cause irritation of the skin, eyes, nose, and throat. Avoid prolonged or repeated exposure to the vapors. Damage may result from forceful handling of the catheter. Prevent kinking of the catheter when removing it from the packaging. This device was designed for single patient use only. Do not reuse, reprocess, or resterilize this product. Reuse, reprocess, or resterilize may compromise the structural integrity of the device and/or create a risk of contamination of the device, which could result in patient injury, illness, or death. The bioprosthesis size must be appropriate to fit the patient’s anatomy. Proper sizing of the device is the responsibility of the physician. Refer to Instructions for Use for available sizes. Failure to implant a device within the sizing matrix could lead to adverse effects such as those listed below. Patients must present with access vessel diameters of ≥6.0 mm for the CoreValve Evolut R system when using Model ENVEOR-US, or ≥5.5 mm when using Model ENVEOR-N-US, or patients must present with an ascending aortic (direct aortic) access site ≥60 mm from the basal plane for both systems. Implantation of the bioprosthesis should be avoided in patients with aortic root angulation (angle between plane of aortic valve annulus and horizontal plane/vertebrae) of >30° for right subclavian/axillary access or >70° for femoral and left subclavian/axillary access. Use caution when considering an auxiliary approach in patients with a patent LIMA graft or patent RIMA graft. For direct aortic access, ensure the access site and trajectory are free of patent RIMA or a preexisting patent RIMA graft.

During Use For direct aortic and subclavian access procedures, care must be exercised when using the tip—retrieval mechanism to ensure adequate clearance to avoid advancement of the catheter tip through the bioprosthesis leaflets during device closure. For direct aortic access procedures, use a separate introducer sheath; do not use the EnVeo R InLine sheath. Adequate rinsing of the bioprosthesis with sterile saline, as described in the Instructions for Use, is mandatory before implantation. During rinsing, do not touch the leaflets or squeeze the bioprosthesis. If a capsule becomes damaged during loading or the capsule fails to close, replace the entire system (bioprosthesis, catheter, and CLS). Do not use a catheter with a damaged capsule. After a bioprosthesis has been inserted into a patient, do not attempt to reload that bioprosthesis on the same or any other catheter. AccuTrak DCS Only: During deployment, if resistance to deployment is encountered (e.g., the micro knob starts clicking or is tight or stuck), apply upward pressure to the macro slider while turning the micro knob. If the bioprosthesis still does not deploy, remove it from the patient and use another system. AccuTrak DCS Only: Once deployment is initiated, retrieval of the bioprosthesis from the patient (e.g., use of the catheter) is not recommended. Retrieval of a partially deployed bioprosthesis could cause mechanical failure of the delivery catheter system, aortic root damage, coronary artery damage, myocardial damage, vascular complications, prosthetic valve dysfunction (including device malposition), embolization, stroke, and/or emergent surgery. AccuTrak DCS Only: During deployment, the bioprosthesis can be advanced or withdrawn as long as annular contact has not been made. Once annular contact is made, the bioprosthesis cannot be advanced in the retrograde direction; if necessary, and the frame has only been deployed ≤2/3 of its length (repositioning can be accomplished once the frame is partially deployed). Once annular contact is made, use caution when moving the bioprosthesis in the antegrade direction. EnVeo R DCS Only: If a misload is detected, unsheath the bioprosthesis and examine the bioprosthesis for damage (for example, permanent frame deformation, frayed sutures, or valve damage). Do not attempt to reload a damaged bioprosthesis. Do not load the bioprosthesis onto the catheter more than 2 times or after it has been inserted into a patient. EnVeo R DCS Only: Use the deployment knob to deploy and recapture the bioprosthesis. Do not use the trigger for deploying or recapturing because it could cause premature placement of the bioprosthesis. EnVeo R DCS Only: Once the radiopaque capsule marker band reaches the distal end of the radiopaque paddle attachment (point of no recapture), retrieval of the bioprosthesis from the patient is not recommended. Retrieval after the point of no recapture of the delivery catheter is not recommended. For direct aortic and subclavian access procedures, care must be exercised when using the tip—recapture mechanism to ensure adequate clearance to avoid advancement of the catheter tip through the bioprosthesis leaflets during device closure. Use caution when using the subclavian/axillary approach in patients with a patent LIMA graft or patent RIMA graft. For direct aortic access, ensure the access site and trajectory are free of patent RIMA or a preexisting patent RIMA graft.
the antegrade direction. However, use caution when moving the bioprosthesis in the antegrade direction. While the catheter is in the patient, ensure the guidewire is extending from the tip. Do not remove the guidewire from the catheter while the catheter is inserted in the patient. Use the hand of the delivery system to reposition the bioprosthesis. Do not use the outer catheter sheath. Once deployment is complete, repositioning of the bioprosthesis (e.g., use of a snare and/or forceps) is not recommended. Repositioning of a deployed valve may cause aortic root damage, coronary artery damage, myocardial damage, vascular complications, prosthetic valve dysfunction (including device malposition), embolization, stroke, and/or emergent surgery. Do not attempt to retrieve or to recapture (EnVeo DCS only) a bioprosthesis if any one of the outflow struts is protruding from the capsule. If any one of the outflow struts has deployed from the capsule, the bioprosthesis must be released from the catheter before the catheter can be withdrawn. Ensure the capsule is closed before catheter removal. When using a separate introducer sheath, if increased resistance is encountered when removing the catheter through the introducer sheath, do not force passage. Increased resistance may indicate a problem and forced passage may result in damage to the device and/or harm to the patient. If the cause of resistance cannot be determined or corrected, remove the catheter and introducer sheath as a single unit over the guidewire, and inspect the catheter and confirm that it is complete. Clinical long-term durability has not been established for the bioprosthesis. Evaluate bioprosthesis performance as needed during patient follow-up. Postprocedure, administer appropriate antibiotic prophylaxis as needed for patients at risk for prosthetic valve infection and endocarditis. Postprocedure, administer anticoagulation and/or antiplatelet therapy per physician/clinical judgment. Excessive contrast media may cause renal failure. Preprocedure, measure the patient’s creatinine level. During the procedure, monitor contrast media usage. Conduct the procedure under fluoroscopy. The safety and efficacy of a CoreValve or CoreValve Evolut R bioprosthesis implanted within a transcatheter bioprosthesis have not been demonstrated. However, in the event that a CoreValve or CoreValve Evolut R bioprosthesis must be implanted within a transcatheter bioprosthesis to improve valve function, valve size and patient anatomy must be considered before implantation of the bioprosthesis to ensure patient safety (for example, to avoid coronary obstruction). In the event that valve function or sealing is impaired due to excessive calcification or incomplete expansion, a postimplant balloon dilation of the bioprosthesis may improve valve function and sealing. To ensure patient safety, valve size and patient anatomy must be considered when selecting the size of the balloon used for dilatation. The balloon size chosen for dilatation should not exceed the diameter of the native aortic annulus or, for surgical bioprosthetic valves, the manufacturer’s labeled inner diameter. Refer to the specific balloon catheter manufacturer’s labeling for proper instruction on the use of balloon catheter devices. Note: Bench testing has only been conducted to confirm compatibility with NuMED Z-MED II™ Balloon Aortic Valvuloplasty catheters where CoreValve or CoreValve Evolut R bioprosthesis device performance was maintained after dilatation. Data on File. For EnVeo R DCS: For transfemoral access, use caution in patients who present with multiplanar curvature of the aorta, acute angulation of the aortic arch, an ascending aortic aneurysm, or severe calcification in the aorta and/or vasculature. If ≥2 of these factors are present, consider an alternative access route to prevent vascular complications. There will be some resistance when the catheter is advanced through the vasculature. If there is a significant increase in resistance, stop advancement and investigate the cause of the resistance (for example, magnify the area of resistance) before proceeding. Do not force passage. Forcing passage could increase the risk of vascular complications (for example, vessel dissection or rupture). Persistent force on the catheter can cause the catheter to kink, which could increase the risk of vascular complications (for example, vessel dissection or rupture). POTENTIAL ADVERSE EVENTS Potential risks associated with the implantation of the CoreValve or CoreValve Evolut R transcatheter aortic valve may include, but are not limited to, the following: • death • myocardial infarction, cardiac arrest, cardiogenic shock, cardiac tamponade • coronary occlusion, obstruction, or vessel spasm (including acute coronary closure) • cardiovascular injury (including rupture, perforation, tissue erosion, or dissection of vessels, ascending aorta trauma, ventricle, myocardial, or valvular structures that may require intervention) • emergent surgical or transcatheter intervention (for example, coronary artery bypass, heart valve replacement, valve explant, percutaneous coronary intervention [PCI], balloon valvuloplasty) • prosthetic valve dysfunction (regurgitation or stenosis) due to fracture; bending; out-of-round configuration of the valve frame; underexpansion of the valve frame; calcification; pannus; leaflet wear, tear, prolapse, or retraction; poor valve coaptation; suture breaks or disruption; leaks; mal-sizing (prosthesis-patient mismatch); malposition (either too high or too low)/malplacement • prosthetic valve migration/embolization • prosthetic valve endocarditis • prosthetic valve thrombosis • delivery catheter system malfunction resulting in the need for additional re-crossing of the aortic valve and prolonged procedural time • delivery catheter system component migration/embolization • stroke (ischemic or hemorrhagic), transient ischemic attack (TIA), or other neurological deficits • heart failure • cardiac failure or low cardiac output • ancillary device embolization • individual organ (for example, cardiac, respiratory, renal [including acute kidney failure]) or multi-organ insufficiency or failure • major or minor bleeding that may require transfusion or intervention (including life-threatening or disabling bleeding) • vascular access-related complications (eg, dissection, perforation, pain, bleeding, hematoma, pseudoaneurysm, irreversible nerve injury, compartment syndrome, arteriovenous fistula, stenosis) • mitral valve regurgitation or injury • conduction system disturbances (for example, atrioventricular node block, left-bundle branch block, asystole), which may require a permanent pacemaker • infection (including septicemia) • hypotension or hypertension • hemolysis • peripheral ischemia • bowel ischemia • abnormal lab values (including electrolyte imbalance) • allergic reaction to antiplatelet agents, contrast medium, or anesthesia • exposure to radiation through fluoroscopy and angiography • permanent disability. Please reference the CoreValve and CoreValve Evolut R Instructions for Use for more information regarding indications, warnings, precautions and potential adverse events. CAUTION Federal law (USA) restricts this device to sale by or on the order of a physician.